1596 related articles for article (PubMed ID: 31221981)
21. Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer
Gonçalves PG; Reis RM; Bidinotto LT
Anticancer Res; 2022 Nov; 42(11):5291-5304. PubMed ID: 36288884
[TBL] [Abstract][Full Text] [Related]
22. The role of histone H3 lysine demethylases in glioblastoma.
Young D; Guha C; Sidoli S
Cancer Metastasis Rev; 2023 Jun; 42(2):445-454. PubMed ID: 37286866
[TBL] [Abstract][Full Text] [Related]
23. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
[TBL] [Abstract][Full Text] [Related]
24. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Patani N; Jiang WG; Newbold RF; Mokbel K
Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
[TBL] [Abstract][Full Text] [Related]
25. JMJD3 as an epigenetic regulator in development and disease.
Burchfield JS; Li Q; Wang HY; Wang RF
Int J Biochem Cell Biol; 2015 Oct; 67():148-57. PubMed ID: 26193001
[TBL] [Abstract][Full Text] [Related]
26. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
[TBL] [Abstract][Full Text] [Related]
27. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells.
Kim JH; Sharma A; Dhar SS; Lee SH; Gu B; Chan CH; Lin HK; Lee MG
Cancer Res; 2014 Mar; 74(6):1705-17. PubMed ID: 24491801
[TBL] [Abstract][Full Text] [Related]
28. Vitamin C-dependent lysine demethylase 6 (KDM6)-mediated demethylation promotes a chromatin state that supports the endothelial-to-hematopoietic transition.
Zhang T; Huang K; Zhu Y; Wang T; Shan Y; Long B; Li Y; Chen Q; Wang P; Zhao S; Li D; Wu C; Kang B; Gu J; Mai Y; Wang Q; Li J; Zhang Y; Liang Z; Guo L; Wu F; Su S; Wang J; Gao M; Zhong X; Liao B; Chen J; Zhang X; Shu X; Pei D; Nie J; Pan G
J Biol Chem; 2019 Sep; 294(37):13657-13670. PubMed ID: 31341023
[TBL] [Abstract][Full Text] [Related]
29. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of
Fei L; Lu Z; Xu Y; Hou G
Front Genet; 2022; 13():920897. PubMed ID: 36035140
[No Abstract] [Full Text] [Related]
30. The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
Schulz WA; Lang A; Koch J; Greife A
Int J Cancer; 2019 Aug; 145(3):614-620. PubMed ID: 30628063
[TBL] [Abstract][Full Text] [Related]
31. The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy.
Chen LJ; Xu XY; Zhong XD; Liu YJ; Zhu MH; Tao F; Li CY; She QS; Yang GJ; Chen J
Bioorg Chem; 2023 Apr; 133():106409. PubMed ID: 36753963
[TBL] [Abstract][Full Text] [Related]
32. Protein profiling reveals potential isomiR-associated cross-talks among RNAs in cholangiocarcinoma.
Guo L; Dou Y; Yang Y; Zhang S; Kang Y; Shen L; Tang L; Zhang Y; Li C; Wang J; Liang T; Li X
Comput Struct Biotechnol J; 2021; 19():5722-5734. PubMed ID: 34745457
[TBL] [Abstract][Full Text] [Related]
33. UTX Mutations in Human Cancer.
Wang L; Shilatifard A
Cancer Cell; 2019 Feb; 35(2):168-176. PubMed ID: 30753822
[TBL] [Abstract][Full Text] [Related]
34. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.
Dalgliesh GL; Furge K; Greenman C; Chen L; Bignell G; Butler A; Davies H; Edkins S; Hardy C; Latimer C; Teague J; Andrews J; Barthorpe S; Beare D; Buck G; Campbell PJ; Forbes S; Jia M; Jones D; Knott H; Kok CY; Lau KW; Leroy C; Lin ML; McBride DJ; Maddison M; Maguire S; McLay K; Menzies A; Mironenko T; Mulderrig L; Mudie L; O'Meara S; Pleasance E; Rajasingham A; Shepherd R; Smith R; Stebbings L; Stephens P; Tang G; Tarpey PS; Turrell K; Dykema KJ; Khoo SK; Petillo D; Wondergem B; Anema J; Kahnoski RJ; Teh BT; Stratton MR; Futreal PA
Nature; 2010 Jan; 463(7279):360-3. PubMed ID: 20054297
[TBL] [Abstract][Full Text] [Related]
35. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
36. ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
Huang Y; Chen D; Bai Y; Zhang Y; Zheng Z; Fu Q; Yi B; Jiang Y; Zhang Z; Zhu J
BMC Cancer; 2024 Apr; 24(1):452. PubMed ID: 38605349
[TBL] [Abstract][Full Text] [Related]
37. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
Liao L; Testa JR; Yang H
Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
39. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
40. Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
Lee SW; Park DY; Kim MY; Kang C
Gastric Cancer; 2019 May; 22(3):640-644. PubMed ID: 30374835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
